

Resmetirom is currently in Phase 3 clinical development

Compound/indication	Clinical study	Pre-clinical	Phase 1	Phase 2	Phase 3	Description
Resmetirom (MGL-3196) THR-β agonist Treatment of NASH	Phase 2 MGL-3196-05 NCT02912260	Completed				■ MRI-PDFF, liver biopsy: endpoints achieved ^{1,2} <ul style="list-style-type: none"> 36 weeks with 36-week OLE
	Phase 3 MAESTRO-NASH NCT03900429	Recruiting				■ Treatment of NASH with F2-3: ³ <ul style="list-style-type: none"> 52-week Phase 3; 54-month outcomes Serial liver biopsy
	Phase 3 MAESTRO-NAFLD-1 (presumed NASH) NCT04197479	Ongoing				■ Treatment of NASH: ³ <ul style="list-style-type: none"> Safety, lipids and NASH biomarker and imaging study 52 weeks Enrollment of double-blind arms completed Open-label 100 mg arm; includes NASH cirrhotics

MAESTRO Phase 3 studies provide a comprehensive data set to support efficacy and safety, consistent with regulatory requirements to support accelerated approval of Resmetirom for treatment of patients with NASH with significant liver fibrosis